Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith T Flaherty

Showing results (231-240 of 418) with videos related to

Pageof 42
Sort By:
The Journal of Clinical Investigation|February 24, 2015
Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanomaLawrence N Kwong, Genevieve M Boland, Dennie T Frederick, et al.
Plos One|October 14, 2015
Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination TreatmentAdam A Friedman, Arnaud Amzallag, Iulian Pruteanu-Malinici, et al.
European Urology|March 12, 2021
Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell CarcinomaAndres F Correa, Opeyemi A Jegede, Naomi B Haas, et al.
Molecular Cancer Therapeutics|November 3, 2022
The AACR Journals: Advancing Progress Toward the AACR's 115-Year MissionKenneth C Anderson, Lewis C Cantley, Riccardo Dalla-Favera, et al.
Cancer Discovery|March 27, 2012
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenibRyan B Corcoran, Hiromichi Ebi, Alexa B Turke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2008
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxelKeith T Flaherty, Joan Schiller, Lynn M Schuchter, et al.
Cancer Immunology Research|November 2, 2022
The AACR Journals: Advancing Progress Toward the AACR's 115-Year MissionKenneth C Anderson, Lewis C Cantley, Riccardo Dalla-Favera, et al.
The Journal of Experimental Medicine|April 29, 2017
An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibitionHelen L Young, Emily J Rowling, Mattia Bugatti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2024
Improving Collection and Analysis of Overall Survival DataLisa R Rodriguez, Nicole J Gormley, Ruixiao Lu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2019
Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G<sub>4</sub> Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB TrialXinan Sheng, Xieqiao Yan, Zhihong Chi, et al.
Pageof 42

Showing results (231-240 of 418) with videos related to

Sort By:
Pageof 42
The Journal of Clinical Investigation|February 24, 2015
Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanomaLawrence N Kwong, Genevieve M Boland, Dennie T Frederick, et al.
Plos One|October 14, 2015
Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination TreatmentAdam A Friedman, Arnaud Amzallag, Iulian Pruteanu-Malinici, et al.
European Urology|March 12, 2021
Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell CarcinomaAndres F Correa, Opeyemi A Jegede, Naomi B Haas, et al.
Molecular Cancer Therapeutics|November 3, 2022
The AACR Journals: Advancing Progress Toward the AACR's 115-Year MissionKenneth C Anderson, Lewis C Cantley, Riccardo Dalla-Favera, et al.
Cancer Discovery|March 27, 2012
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenibRyan B Corcoran, Hiromichi Ebi, Alexa B Turke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2008
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxelKeith T Flaherty, Joan Schiller, Lynn M Schuchter, et al.
Cancer Immunology Research|November 2, 2022
The AACR Journals: Advancing Progress Toward the AACR's 115-Year MissionKenneth C Anderson, Lewis C Cantley, Riccardo Dalla-Favera, et al.
The Journal of Experimental Medicine|April 29, 2017
An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibitionHelen L Young, Emily J Rowling, Mattia Bugatti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2024
Improving Collection and Analysis of Overall Survival DataLisa R Rodriguez, Nicole J Gormley, Ruixiao Lu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2019
Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G<sub>4</sub> Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB TrialXinan Sheng, Xieqiao Yan, Zhihong Chi, et al.
Pageof 42